nitroderm tts 10 mg/24 ur transdermalni obliž
novartis pharma gmbh - gliceriltrinitrat - transdermalni obliž - gliceriltrinitrat 50 mg / 1 obliž - gliceriltrinitrat
miacalcic 200 i.e./odmerek pršilo za nos, raztopina
novartis pharma gmbh - lososov kalcitonin - pršilo za nos, raztopina - lososov kalcitonin 200 i.e. / 1 ml - sintezni lososov kalcitonin
focetria
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - cepiva proti gripi - preprečevanje gripe, ki jo povzroča virus a (h1n1v) 2009. focetria je treba uporabljati v skladu z uradnimi smernice.
duotrav
novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmologi - zmanjšanje očesnega tlaka (cw) pri odraslih bolnikih z glavkomom odprtega zakotja ali očesno hipertenzijo, ki se ne odzivajo na aktualne beta-blokatorji ali analogi prostaglandinov.
adakveo
novartis europharm limited - crizanlizumab - anemija, srčna celica - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
sandostatin 0,05 mg/ml raztopina za injiciranje/infundiranje
novartis pharma gmbh - oktreotid - raztopina za injiciranje/infundiranje - oktreotid 0,05 mg / 1 ml - oktreotid
locametz
novartis europharm limited - gozetotide - radionuklidno slikanje - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
co-diovan 80 mg/12,5 mg filmsko obložene tablete
novartis pharma gmbh - hidroklorotiazid; valsartan - filmsko obložena tableta - hidroklorotiazid 12,5 mg / 1 tableta valsartan80 mg / 1 tableta; valsartan 80 mg / 1 tableta - valsartan in diuretiki
co-diovan 160 mg/12,5 mg filmsko obložene tablete
novartis pharma gmbh - hidroklorotiazid; valsartan - filmsko obložena tableta - hidroklorotiazid 12,5 mg / 1 tableta valsartan160 mg / 1 tableta; valsartan 160 mg / 1 tableta - valsartan in diuretiki
co-diovan 320 mg/25 mg filmsko obložene tablete
novartis pharma gmbh - hidroklorotiazid; valsartan - filmsko obložena tableta - hidroklorotiazid 25 mg / 1 tableta valsartan320 mg / 1 tableta; valsartan 320 mg / 1 tableta - valsartan in diuretiki